ENAGenomicsHemato-oncology, IDIBAPShttps://www.ebi.ac.uk/ena/browser/view/PRJNA369382Homo sapiensMantle Cell lymphoma (MCL) were treated with the BTK inhibitor 1mM CC-292 for 48h We used microarrays to uncover the mechanisms underlying CC-292 activity in Mantle Cell lymphoma (MCL) Overall design: Global RNA expression was done in two MCL cell lines treated in vitro with CC-292 for 48hENAfalseHomo sapiensThe BTK Inhibitor CC-292 shows activity in Mantle Cell Lymphoma and synergizes with Lenalidomide and NIK Inhibitors depending on NFκB mutational status2025-09-242017-09-02PRJNA369382GSE943289606